Brixton BiosciencesOctober 26, 2023BRIXTON BIOSCIENCES’ COOLIO™ THERAPY GRANTED BREAKTHOUGH DEVICE DESIGNATION BY FDA
Sera PrognosticsMay 15, 2023Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
Sera PrognosticsFebruary 15, 2023Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
ConformalFebruary 3, 2023Conformal Medical Announces Positive One-Year Data from its Left Atrial Appendage Closure Performed Under Conscious Sedation Study
ConformalJanuary 8, 2023JSCAI Publishes Peer-Reviewed Article Highlighting Effective Performance of Conformal Medical’s Left Atrial Appendage (CLAAS®) Device
Sera PrognosticsNovember 15, 2022Sera Prognostics Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the PRETRM® Test-and-Treat Strategy Across Diverse Populations
AtaCor MedicalNovember 3, 2022AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies
Sera PrognosticsSeptember 22, 2022Banner Health, Sera Prognosics Team Up to Provide PreTRM® Test to Cover Pregnant Members
PanTher TherapeuticsSeptember 1, 2022PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment
